Target Price | $765.00 |
Price | $560.00 |
Potential | 36.61% |
Number of Estimates | 29 |
29 Analysts have issued a price target Regeneron Pharmaceuticals 2026 . The average Regeneron Pharmaceuticals target price is $765.00. This is 36.61% higher than the current stock price. The highest price target is $1,063.65 89.94% , the lowest is $548.43 2.07% . | |
A rating was issued by 35 analysts: 27 Analysts recommend Regeneron Pharmaceuticals to buy, 7 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Regeneron Pharmaceuticals stock has an average upside potential 2026 of 36.61% . Most analysts recommend the Regeneron Pharmaceuticals stock at Purchase. |
30 Analysts have issued a sales forecast Regeneron Pharmaceuticals 2025 . The average Regeneron Pharmaceuticals sales estimate is $14.2b . This is 0.35% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $15.3b 7.49% , the lowest is $13.3b 6.45% .
This results in the following potential growth metrics:
2024 | $14.2b | 8.27% |
---|---|---|
2025 | $14.2b | 0.27% |
2026 | $14.9b | 4.97% |
2027 | $16.3b | 9.69% |
2028 | $17.4b | 6.94% |
2029 | $18.5b | 6.07% |
2030 | $19.3b | 4.50% |
2031 | $19.7b | 2.16% |
2032 | $19.5b | 1.33% |
14 Analysts have issued an Regeneron Pharmaceuticals EBITDA forecast 2025. The average Regeneron Pharmaceuticals EBITDA estimate is $4.6b . This is 0.21% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $6.3b 37.21% , the lowest is $3.1b 31.57% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $4.7b | 1.17% |
---|---|---|
2025 | $4.6b | 3.00% |
2026 | $5.3b | 15.92% |
2027 | $6.1b | 15.49% |
2028 | $6.6b | 7.96% |
2029 | $7.1b | 7.54% |
2030 | $7.4b | 4.67% |
2031 | $7.7b | 3.68% |
2032 | $6.8b | 11.01% |
2024 | 33.10% | 8.72% |
---|---|---|
2025 | 32.19% | 2.75% |
2026 | 35.55% | 10.44% |
2027 | 37.44% | 5.32% |
2028 | 37.79% | 0.93% |
2029 | 38.32% | 1.40% |
2030 | 38.38% | 0.16% |
2031 | 38.95% | 1.49% |
2032 | 35.13% | 9.81% |
31 Regeneron Pharmaceuticals Analysts have issued a net profit forecast 2025. The average Regeneron Pharmaceuticals net profit estimate is $4.3b . This is 4.63% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $4.7b 6.24% , the lowest is $3.6b 18.15% .
This results in the following potential growth metrics and future Net Margins:
2024 | $4.4b | 11.61% |
---|---|---|
2025 | $4.3b | 3.64% |
2026 | $4.5b | 5.77% |
2027 | $5.3b | 17.95% |
2028 | $5.8b | 9.81% |
2029 | $6.4b | 9.46% |
2030 | $6.9b | 7.92% |
2031 | $7.3b | 5.66% |
2032 | $7.2b | 1.62% |
2024 | 31.07% | 3.08% |
---|---|---|
2025 | 30.02% | 3.38% |
2026 | 30.25% | 0.77% |
2027 | 32.53% | 7.54% |
2028 | 33.40% | 2.67% |
2029 | 34.47% | 3.20% |
2030 | 35.60% | 3.28% |
2031 | 36.82% | 3.43% |
2032 | 36.71% | 0.30% |
31 Analysts have issued a Regeneron Pharmaceuticals forecast for earnings per share. The average Regeneron Pharmaceuticals EPS is $39.96 . This is 2.66% lower than earnings per share in the financial year 2024. The highest EPS forecast is $44.52 8.45% , the lowest is $34.30 16.44% .
This results in the following potential growth metrics and future valuations:
2024 | $38.34 | 10.27% |
---|---|---|
2025 | $39.96 | 4.23% |
2026 | $42.27 | 5.78% |
2027 | $49.86 | 17.96% |
2028 | $54.75 | 9.81% |
2029 | $59.93 | 9.46% |
2030 | $64.67 | 7.91% |
2031 | $68.34 | 5.67% |
2032 | $67.23 | 1.62% |
Current | 13.64 | 54.86% |
---|---|---|
2025 | 14.01 | 2.70% |
2026 | 13.25 | 5.42% |
2027 | 11.23 | 15.25% |
2028 | 10.23 | 8.90% |
2029 | 9.34 | 8.70% |
2030 | 8.66 | 7.28% |
2031 | 8.19 | 5.43% |
2032 | 8.33 | 1.71% |
Based on analysts' sales estimates for 2025, the Regeneron Pharmaceuticals stock is valued at an EV/Sales of 3.85 and an P/S ratio of 4.19 .
This results in the following potential growth metrics and future valuations:
Current | 3.84 | 55.96% |
---|---|---|
2025 | 3.85 | 0.36% |
2026 | 3.67 | 4.74% |
2027 | 3.35 | 8.83% |
2028 | 3.13 | 6.48% |
2029 | 2.95 | 5.73% |
2030 | 2.82 | 4.31% |
2031 | 2.76 | 2.12% |
2032 | 2.80 | 1.35% |
Current | 4.18 | 54.84% |
---|---|---|
2025 | 4.19 | 0.35% |
2026 | 3.99 | 4.73% |
2027 | 3.64 | 8.83% |
2028 | 3.40 | 6.48% |
2029 | 3.21 | 5.73% |
2030 | 3.07 | 4.31% |
2031 | 3.01 | 2.12% |
2032 | 3.05 | 1.35% |
Regeneron Pharmaceuticals...
Analyst | Rating | Action | Date |
---|---|---|---|
Jefferies |
Buy
➜
Buy
|
Unchanged | Aug 27 2025 |
Bernstein |
Outperform
➜
Outperform
|
Unchanged | Aug 27 2025 |
Truist Securities |
Buy
➜
Buy
|
Unchanged | Aug 11 2025 |
RBC Capital |
Sector Perform
➜
Sector Perform
|
Unchanged | Aug 04 2025 |
Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Aug 04 2025 |
Guggenheim |
Buy
➜
Buy
|
Unchanged | Aug 04 2025 |
BMO Capital |
Outperform
➜
Outperform
|
Unchanged | Aug 04 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Jefferies:
Buy
➜
Buy
|
Aug 27 2025 |
Unchanged
Bernstein:
Outperform
➜
Outperform
|
Aug 27 2025 |
Unchanged
Truist Securities:
Buy
➜
Buy
|
Aug 11 2025 |
Unchanged
RBC Capital:
Sector Perform
➜
Sector Perform
|
Aug 04 2025 |
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Aug 04 2025 |
Unchanged
Guggenheim:
Buy
➜
Buy
|
Aug 04 2025 |
Unchanged
BMO Capital:
Outperform
➜
Outperform
|
Aug 04 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.